DAE HWA Pharmaceutical Co. Ltd (067080) — Capital Reinvestment Ratio
Latest as of March 2026:
1.09x
DAE HWA Pharmaceutical Co. Ltd (067080) has a Capital Reinvestment Ratio of 1.09x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩314.63 Million) in capital expenditures (₩343.17 Million). See 067080 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.09x
Capex / Operating Cash Flow
Operating Cash Flow
₩314.63 Million
KRW
Capital Expenditures
₩343.17 Million
KRW
Data as of
Mar 2026
Most recent filing
DAE HWA Pharmaceutical Co. Ltd Capital Reinvestment Ratio (2011–2025)
This chart tracks DAE HWA Pharmaceutical Co. Ltd's Capital Reinvestment Ratio across 13 annual periods.
Annual Capital Reinvestment Ratio for DAE HWA Pharmaceutical Co. Ltd (2011–2025)
Year-by-year Capital Reinvestment Ratio for DAE HWA Pharmaceutical Co. Ltd from 2011 to 2025. For live market cap and broader valuation context, see market value of DAE HWA Pharmaceutical Co. Ltd.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | ₩5.43 Billion | ₩4.73 Billion | ▼ -13.2% |
| 2024 | 1.00x | ₩6.13 Billion | ₩6.14 Billion | ▼ -74.7% |
| 2022 | 3.97x | ₩8.05 Billion | ₩31.94 Billion | ▲ +188.1% |
| 2021 | 1.38x | ₩10.45 Billion | ₩14.40 Billion | ▼ -61.5% |
| 2020 | 3.58x | ₩2.90 Billion | ₩10.38 Billion | ▲ +680.2% |
| 2018 | 0.46x | ₩10.49 Billion | ₩4.81 Billion | ▼ -30.8% |
| 2017 | 0.66x | ₩10.94 Billion | ₩7.26 Billion | ▲ +44.7% |
| 2016 | 0.46x | ₩8.79 Billion | ₩4.03 Billion | ▼ -75.9% |
| 2015 | 1.90x | ₩2.43 Billion | ₩4.62 Billion | ▲ +307.6% |
| 2014 | 0.47x | ₩6.18 Billion | ₩2.88 Billion | ▲ +434.8% |
| 2013 | 0.09x | ₩13.57 Billion | ₩1.18 Billion | ▼ -62.9% |
| 2012 | 0.23x | ₩5.77 Billion | ₩1.36 Billion | ▼ -91.3% |
| 2011 | 2.71x | ₩3.43 Billion | ₩9.31 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow